Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | DAO | P14920 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472954 | 0.83 | DAO (0.63) | MAPTDAOKDM4EMEN1KMT2A | |
| SCHEMBL1630492 | 0.81 | KDR (0.42) | MAPTDAOKDM4EMEN1KMT2A | |
| SCHEMBL2043829 | 0.80 | GSK3B (0.59) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL15988677 | 0.79 | GSK3B (0.48) | MAPTDAOKDM4EMEN1KMT2A | |
| SCHEMBL23617317 | 0.79 | GSK3B (0.44) | MAPTDAOKDM4EMEN1KMT2A | |
| SCHEMBL261464 | 0.78 | CSNK2A2 (0.45) | MAPTDAOKDM4EMEN1KMT2A | |
| SCHEMBL12294979 | 0.78 | GSK3B (0.67) | MAPTDAOKDM4EMEN1KMT2A | |
| SCHEMBL22870146 | 0.78 | KDM4E (0.54) | MAPTDAOKDM4EMEN1KMT2A | |
| SCHEMBL14523581 | 0.78 | DAO (0.38) | MAPTDAOKDM4EMEN1KMT2A | |
| SCHEMBL24322051 | 0.78 | MAPT (0.38) | MAPTDAOKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117800960-A | Preparation method of isoxazoline anthelmintic rotigorskite | 常州齐晖药业有限公司 | 2024-04-02 | — | — | CN | claimed |
| US-12552757-B2 | NRF2-activating compound | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2026-02-17 | — | — | US | disclosed |
| CN-120040438-A | Isoxazole antiparasitic agents Synthesis method of medicine lotirana | 华南农业大学 | 2025-05-27 | — | — | CN | disclosed |
| US-12304903-B2 | Process for making an isoxazoline compound and intermediate thereof | ELANCO US INC. (US) | 2025-05-20 | — | — | US | disclosed |
| CN-119798241-A | Method for simply and conveniently preparing high-purity rotigorskite | 北京元延医药科技股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20250109125-A1 | PROCESS FOR MAKING AN ISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | ELANCO US INC. | 2025-04-03 | — | — | US | disclosed |
| US-20240308993-A1 | PROCESS FOR MAKING DIARYL ISOXAZOLINE DERIVATIVE | ELANCO US INC. | 2024-09-19 | — | — | US | disclosed |
| EP-4384514-A1 | PROCESS FOR MAKING DIARYL ISOXAZOLINE DERIVATIVE | ELANCO US INC. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| CN-117813303-A | Process for preparing diaryl isoxazoline derivatives | 礼蓝美国公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2011157748-A1 | 5-ARYL ISOXAZOLINES FOR CONTROLLING PESTS | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
| EP-2379537-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20110245239-A1 | ORGANIC COMPOUNDS | ELANCO TIERGESUNDHEIT AG (CH) | 2011-10-06 | — | — | US | disclosed |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-11 | — | — | US | disclosed |
| WO-2010070068-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-06-24 | — | — | WO | disclosed |
| WO-2009017818-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007087429-A2 | PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109125-A1 | PROCESS FOR MAKING AN ISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | CYP3A7, CYP4Z1, CYP2A7 | MAPT 2911/4885DAO 296/4885KDM4E 668/4885 |
| US-20240308993-A1 | PROCESS FOR MAKING DIARYL ISOXAZOLINE DERIVATIVE | CYP3A7, CYP1B1, CYP1A2 | MAPT 3715/4885DAO 781/4885KDM4E 1579/4885 |
| US-12552757-B2 | NRF2-activating compound | NFE2L2, NFE2, KEAP1 | MAPT 2863/4885DAO 2771/4885KDM4E 1987/4885 |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | NLRP3, CCR1, NLRP1 | MAPT 1355/4885DAO 3209/4885KDM4E 859/4885 |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | NFE2L2, KEAP1, NFE2 | MAPT 2512/4885DAO 2854/4885KDM4E 3587/4885 |
| US-20110245239-A1 | ORGANIC COMPOUNDS | ACHE, VDAC1, VDAC2 | MAPT 1342/4885DAO 270/4885KDM4E 2444/4885 |
| US-12304903-B2 | Process for making an isoxazoline compound and intermediate thereof | CYP3A7, CYP4Z1, CYP2A7 | MAPT 2911/4885DAO 296/4885KDM4E 668/4885 |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | AHR, NFATC1, ICOS | MAPT 4007/4885DAO 1805/4885KDM4E 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.